Improved treatment and prognosis after acute myocardial infarction in Estonia: cross-sectional study from a high risk country by Aet Saar et al.
RESEARCH ARTICLE Open Access
Improved treatment and prognosis after
acute myocardial infarction in Estonia:
cross-sectional study from a high risk
country
Aet Saar1*, Toomas Marandi1,2, Tiia Ainla1,2, Krista Fischer3, Mai Blöndal1 and Jaan Eha1,4
Abstract
Background: The aim of the study was to explore trends in short- and long-term mortality after hospitalization for
acute myocardial infarction (AMI) over the period 2001─2011 in Estonian secondary and tertiary care hospitals
while adjusting for changes in baseline characteristics.
Methods: In this nationwide cross-sectional study random samples of patients hospitalized due to AMI in years
2001, 2007 and 2011 were identified and followed for 1 year. Trends in 30-day and 1-year all-cause mortality were
analysed using Cox proportional hazards regression model.
Results: The final analysis included 423, 687 and 665 patients in years 2001, 2007 and 2011 respectively. During the
study period, the prevalence of most comorbidities remained unchanged while the in-hospital and outpatient
treatment improved significantly. For example, the proportion of tertiary care hospital AMI patients who underwent
revascularization was almost three times higher in 2011 compared to 2001. The proportion of secondary care
patients who were referred to a tertiary care centre for more advanced care increased from 5.8 to 40.1 %
(p for trend <0.001). Meanwhile, the 1-year mortality rates decreased from 29.5 to 20.2 % (adjusted p = 0.004)
in the tertiary and from 32.4 to 23.1 % (adjusted p = 0.006) in the secondary care. The decrease in the 30-day
mortality rates was statistically significant only in the secondary care hospitals.
Conclusions: The use of evidence-based treatments in Estonian AMI patients improved between 2001 and 2011.
At the same time, we observed a significant reduction in the long-term mortality rates, both for patients primarily
hospitalized into secondary as well as into tertiary care hospitals.
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Background
Coronary artery disease (CAD) is currently the number
one cause of death in Europe [1]. Even though the fatality
rates for acute myocardial infarction (AMI) have markedly
decreased during the last few decades, Estonian death
rates from CAD are still among the highest in Europe [2].
Modelling studies from different European countries have
attributed declining trends in cardiovascular mortality to
improved treatment and changes in cardiovascular risk
factors [3, 4].
Important components of AMI treatment are early diag-
nosis, timely reperfusion and use of evidence-based medi-
cations [5, 6]. Earlier studies [7–9] from Estonia show
improvement in AMI treatment, emphasizing better access
to invasive diagnostics and treatment and wider use of
evidence-based medications over time. However, no signifi-
cant improvement in short- and long-term mortality in
Estonian AMI population was seen [8, 9]. A recent over-
view about quality of care and mortality following AMI
from Central and Eastern European countries describes
lack of comparable data and wide variation in acute cardiac
care, in both between and within European countries [10].* Correspondence: aetsaar@gmail.com
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The aim of the present study is to explore trends in
short- and long-term mortality rates after hospitalization
for AMI over the period 2001─2011 in Estonian second-
ary and tertiary care hospitals while considering changes
in baseline characteristics and treatment.
Methods
We conducted a nationwide cross-sectional study based
on hospital records. The formation of the study sample
is described in Fig. 1.
The list of all the AMI cases for each year was ob-
tained from the Estonian Health Insurance Fund (EHIF)
database. During the time period studied, approximately
95 % of the Estonian population was covered with the
health insurance. The validity of AMI diagnoses in EHIF
database has been established previously [11]. According
to the EHIF database, the total number of AMI cases
hospitalized (main diagnosis code I21─I22 according to
the International Statistical Classification of Diseases
[ICD] and Related Health Problems 10th revision) was as
2365 in 2001, 3251 in 2007 and 3488 in 2011. All Estonian
hospitals are using ICD codes I21─I22 (acute and subse-
quent myocardial infarction) with extension to diagnose
AMI. As we intended to evaluate treatment of AMI in the
hospital where the patient was primarily hospitalized, the
following exclusion criteria were applied: (1) patients who
were not primarily hospitalized into one of the study hos-
pitals; (2) patients who were re-admitted with AMI diag-
nosis within 28 days after the first admission (only the
second admission was excluded); (3) patients whose
length of hospital stay was less than 3 days if they were
discharged alive and were not transferred, which
made the diagnosis of AMI very unlikely considering
the local clinical practice.
From the remaining cases a study sample was formed
by the use of random selection. The sampling was
performed in clusters in order to get cross-sectional
overview from all cases admitted into different types
of hospitals. To ensure data comparability across
years, the formation of the study sample was similar
in all years studied.
In order to have a representative sample of all Estonian
AMI patients, we included hospitals that treat the major
proportion of annual AMI cases. In 2001, there were two
tertiary and seven secondary care hospitals responsible for
the treatment of most AMI cases in Estonia. The tertiary
care hospitals had percutaneous coronary intervention
(PCI) availability during working hours, while the second-
ary care hospitals did not have PCI availability. In 2007,
the study included sixteen hospitals, two of tertiary and
fourteen of secondary care. By the year 2007, both tertiary
care hospitals had 24/7 PCI availability and one secondary
care hospital had PCI available during working hours. In
2011, the study included thirteen secondary and two ter-
tiary care hospitals. The tertiary care hospitals and one
secondary care hospital had 24/7 PCI availability and two
secondary care hospitals had PCI availability once a week.
Thus, ten out of thirteen secondary care hospitals did not
have PCI availability.
In Estonia there are two tertiary care hospitals, which
did not change during the study period. The number of
secondary care hospitals varied in the years studied due to
the restructuring of the hospital network of Estonia. Also,
it should be noted, that the recommendations of the
Fig. 1 Formation of the study sample. AMI – acute myocardial
infarction, EHIF – Estonian Health Insurance Fund
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Estonian Society of Cardiology to admit patients with
ST-segment elevation myocardial infarction (STEMI)
for primary PCI to two tertiary care hospitals remained
consistent during the study period.
The criteria applied for AMI diagnosis on 2001 and 2007
study populations were based on the consensus document
published by the European Society of Cardiology in 2000
[12]. For 2011 cohort, the criteria were based on the
redefinition of myocardial infarction published in
2007 [13]. In the data abstraction process, the med-
ical records from study hospitals were obtained and
data were collected retrospectively by experts accord-
ing to the acute coronary syndromes data standards
that were later presented in the CARDS Project [14].
The experts were certified cardiologists or cardiolo-
gists in training and all had received additional train-
ing on the data collection for this study. Every AMI
case was reviewed by one expert, which was followed
by random re-abstraction by another expert for data
quality monitoring purposes. If discrepancies were de-
termined, the experts were additionally trained. Data
on mortality were obtained from the Estonian Popula-
tion Registry. As the aim of the study was to evaluate
the quality of care of the first hospital where the pa-
tient was admitted, data collection stopped after the
patient was referred from a secondary care to a ter-
tiary care hospital. Data on discharge medications
were available only for those secondary care patients
who were not referred to a tertiary care hospital.
The study was approved by the Research Ethics Com-
mittee of the University of Tartu.
Statistical analysis
For all patient characteristics and outcome variables of
interest, comparisons between three years (2001, 2007,
2011) and two types of hospital (tertiary vs secondary
care) of primary hospitalization were made.
Categorical variables were summarized by percent-
ages and continuous variables by means and standard
deviations. Differences in continuous variables were
examined by classical linear regression and differences
in binary variables by logistic regression. Categorical
variables with more than two categories were analysed
using the Chi-Square test.
As main outcome variables in this study, 30-day and
1-year all-cause mortality was analysed. In addition to
crude mortality rates, baseline adjusted (age, sex, AMI
subtype, diabetes, hypertension, previous heart failure,
previous myocardial infarction) rates were compared
using the Cox proportional hazards regression model.
Patients initially hospitalized into a secondary care
hospital but transferred and treated in tertiary care
hospital, were included in the mortality analysis as
secondary care patients. Two sided P values <0.05 were
considered statistically significant.
For all statistical analyses, R software (ver. 3.1.1) was
used [15].
Results
Final study sample included 423, 687 and 665 cases from
years 2001, 2007 and 2011 respectively.
Baseline characteristics
Baseline characteristics are presented in Tables 1 and 2.
Although the mean age of the study sample increased in
both hospital types during the period, there were no sig-
nificant changes in the frequency of most comorbidities.
The results show increased proportion of patients with
non-ST-segment-elevation acute myocardial infarction
(NSTEMI) compared to that of patients with STEMI in
both hospital types over time.
Treatment
Guideline-recommended treatments were more likely to
be used for patients hospitalized in 2011 than in the
earlier years in both hospital types (Tables 3 and 4). Car-
diac catheterization and percutaneous revascularization
became a dominant strategy in the tertiary care setting.
The reperfusion rates for STEMI increased from 42.3 to
63.1 % (p < 0.001) in the tertiary care hospitals, while
there was no statistically significant change in the sec-
ondary care hospitals. Meanwhile, there was an import-
ant increase in the proportion of patients who were
referred from a secondary to a tertiary care hospital
for further diagnostics and treatment (from 5.8 to
Table 1 Baseline characteristics of acute myocardial infarction
patients hospitalized primarily into tertiary care hospitals
Year 2001 Year 2007 Year 2011 P value
for trendn = 210 n = 327 n = 302
Hospital days, mean, (SD) 11.4 (9.1) 10.0 (8.4) 9.2 (6.5) 0.002
Mean age (SD), years 68.3 (12.7) 69.7 (12.0) 71.0 (12.0) 0.015
≥75 years, % 31.0 37.0 41.4 0.017
Men, % 66.7 58.1 62.3 0.3
STEMI, % 61.9 49.5 53.0 0.043
Diabetes, % 19.0 27.2 26.2 0.065
Arterial hypertension, % 70.0 70.0 75.2 0.206
Previous MI, % 29.5 29.4 29.1 0.925
Previous heart failure, % 27.1 28.1 25.2 0.626
Time to presentation, %
≤ 3 h 47.6 41.9 44.7 0.723
3–12 h 23.8 24.8 23.2
> 12 h 28.6 33.3 32.1
MI myocardial infarction, STEMI ST-segment elevation myocardial infarction,
SD standard deviation
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40.1 %, p < 0.001). The prescription rates of cardiovascular
medications recommended by guidelines at discharge
increased in all five drug groups in both hospital
types (Table 5).
Mortality
There was a statistically significant decrease from 20.2
to 12.4 % (adjusted p = 0.003) in 30-day mortality rate in
the secondary care setting during the period studied
(Table 6). 30-day mortality reduction was not statistically
significant in the tertiary care hospitals. Results from
long-term mortality analysis show decrease from 29.5 to
20.2 % (adjusted p = 0.004) in the tertiary care and from
32.4 to 23.1 % (adjusted p = 0.006) in the secondary care
hospitals in 1-year mortality rates.
From the results of mortality analysis comparing dif-
ferent years and hospital types we found marked decline
in mortality rates in both types of hospitals, which took
place first in the tertiary and then in the secondary care.
Mortality rates were similarly high in 2001. 30-day and
1-year mortality had decreased by year 2007 only in the
tertiary care. By 2011, mortality rates had declined in
both hospital types; mortality gap between the secondary
and the tertiary care had disappeared (Fig. 2).
Discussion
In this countrywide analysis covering period 2001─2011,
we demonstrated a decrease in short- and long-term mor-
tality of AMI patients. The mortality reduction is consist-
ent with reports from other countries and is generally
attributed to many factors, including improved risk factor
management, more frequent use of pharmacological
agents and more widespread availability of revasculariza-
tion methods, especially primary PCI [3, 4, 16, 17]. Also,
developments in efficacy and safety of coronary artery
stents may have improved the outcome [18].
The prevalence of STEMI has decreased in both hospital
types, which is counter-balanced by higher proportion of
NSTEMI. Improved coronary risk factor management and
treatment after first coronary event may have contributed
to the observed trend [19]. Another plausible explanation
is the rising mean age, which is consistent with earlier
studies describing higher prevalence of NSTEMI among
the elderly [20]. Third and probably the most important
explanation for the growing ratio of NSTEMI to STEMI is
the more widespread use of high-sensitivity troponin as-
says, which has resulted in more sensitive diagnostics [21].
During last decades, led by the Estonian Society of
Cardiology, much effort has been offered to improve
diagnostics and treatment of AMI. Quality improvement
measures have targeted different aspects of the AMI
management, including prehospital triage and
Table 2 Baseline characteristics of AMI patients hospitalized
primarily into secondary care hospitals
Year 2001 Year 2007 Year 2011 P value
for trendn = 213 n = 360 n = 363
Hospital days, mean, (SD) 11.4 (6.8) 9.4 (7.6) 6.5 (6.3) <0.001
Mean age (SD), years 68.4 (12.4) 71.8 (11.4) 72.8 (12.2) <0.001
≥75 years, % 34.3 45.3 47.4 0.002
Men, % 52.1 51.9 48.5 0.4
STEMI, % 59.6 51.4 44.4 <0.001
Diabetes, % 16.4 31.1 21.5 0.225
Arterial hypertension, % 57.3 75.8 74.7 <0.001
Previous MI, % 23.9 27.2 30.9 0.073
Previous heart failure, % 26.8 31.7 32.2 0.176
Time to presentation, %
≤ 3 h 31.0 30.6 30.0 0.993
3–12 h 25.8 25.0 26.4
> 12 h 43.2 44.4 43.5
MI myocardial infarction, STEMI ST- segment elevation myocardial infarction,
SD standard deviation
Table 3 In-hospital management in tertiary care hospitals
Year 2001 Year 2007 Year 2011 P value
for trendn = 210 n = 327 n = 302
% % %
Medications
Aspirin 87.1 94.2 94.4 0.003
P2Y12-receptor inhibitors 17.1 61.5 70.5 <0.001
Anticoagulants 89.0 93.0 92.7 0.133
Glycoprotein IIb/IIIa inh. 12.4 38.8 29.1 <0.001
Betablockers 79.5 82.6 82.1 0.452
Nitrates 92.4 78.9 76.2 <0.001
ACEi/ARB 70.5 74.9 81.1 0.006
Statins 26.7 67.9 77.2 <0.001
Cardiac catheterization 35.7 78.6 80.8 <0.001
Revascularization 27.6 64.2 73.5 <0.001
PCI 22.4 61.5 67.9 <0.001
CABG 5.2 3.7 6.0 0.722
Echocardiography 81.9 85.3 88.4 0.044
Treatment for STEMI n = 130 n = 162 n = 160
Reperfusion for STEMI 42.3 64.2 63.1 <0.001
Thrombolysis 35.4 7.4 0.6 <0.001
Primary PCI 6.9 56.8 62.5 <0.001
Treatment for NSTEMI n = 80 n = 165 n = 142
PCI 18.8 47.9 53.5 <0.001
CABG 7.5 3.6 9.2 0.56
Anticoagulants – low molecular weight heparins/unfractionated heparin/
fondaparinux, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin
II receptor blockers, P2Y12-receptor inhibitors – ticlopidine/clopidogrel/ticagrelol,
CABG coronary artery bypass grafting, PCI percutaneous coronary intervention,
STEMI ST- segment elevation myocardial infarction, NSTEMI non-ST-segment
elevation myocardial infarction
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establishing STEMI network, therapies during
hospitalization, at discharge and outpatient care. For ex-
ample, local STEMI guideline was published [22], Euro-
pean AMI definitions and guidelines were translated
into Estonian and several educational events throughout
Estonia were organized. At the same time, access to
cardiac catheterization facilities has improved.
Reperfusion rates for STEMI are used as performance
measures of AMI treatment. Findings indicate that re-
perfusion rates in the tertiary care hospitals are now
comparable with respective rates form North, West, and
Central Europe [23, 24]. Results are different for the sec-
ondary care – only approximately 40 % of STEMI pa-
tients are being offered reperfusion, with no increase
during the period studied. However, low reperfusion
rates should be interpreted with caution – in 2011 more
than 40 % of secondary care patients were referred to a
tertiary care centre for further management. We can
hypothesize that patients were transferred before receiv-
ing reperfusion. Nevertheless, such trend is alarming, be-
cause transfer increases the delays and timely PCI is
impossible. Data from international EPICOR registry
suggest that recommended times are often not met
when AMI patients are transferred for primary PCI [25].
Primary PCI is recommended as first line therapy for
STEMI but it should be emphasized that thrombolysis is
also an appropriate and proven reperfusion strategy
[26]. However, more frequent referral to the tertiary
care hospitals is in agreement with guidelines that
recommend an invasive management for STEMI or
high-risk NSTEMI patients [7, 8]. Also, local quality
improvement initiatives have stressed the importance
of timely referral of STEMI patients without contrain-
dications and most NSTEMI patients to tertiary care
centres with catheterization laboratories.
In addition to the reperfusion therapy, the recom-
mended concomitant pharmacological therapy and the
discharge medications play a major role in determining
prognosis. Lower prescription rates of secondary preven-
tion drugs in the secondary care can be partly explained
by differences in the baseline characteristics. Patients in
the secondary care hospitals were older and it has been
shown that elderly patients are less likely to receive
medications recommended by guidelines [27]. Previously
described lower adherence to guidelines in smaller non-









n = 213 n = 360 n = 363
% % %
Medications
Aspirin 88.3 86.4 85.7 0.383
P2Y12-receptor inhibitors 0 10.6 26.4 <0.001
Anticoagulants 85.4 92.8 95.0 <0.001
Glycoprotein IIb/IIIa inh. 0.5 3.1 5.2 0.003
Betablockers 76.1 77.8 73.0 0.384
Nitrates 96.7 85.6 78.8 <0.001
ACEi/ARB 37.1 62.2 55.9 <0.001
Statins 5.6 30.8 49.0 <0.001
Cardiac catheterization 0 6.7 18.5 <0.001
Revascularization 0 4.2 14.3 <0.001
PCI 0 4.2 14.3 <0.001
CABG 0 0 0 -
Echocardiography 52.1 51.9 50.7 0.735
Referred to a tertiary care
hospital
5.8 24.8 40.1 <0.001
Treatment for STEMI n = 127 n = 185 n = 161
Reperfusion for STEMI 44.1 34.1 37.9 0.251
Thrombolysis 44.1 34.1 29.2 0.008
Primary PCI 0 0 8.7 -
Treatment for NSTEMI n = 86 n = 175 n = 202
PCI 0 4.6 10.4 0.002
CABG 0 0 0 -
Referred to a tertiary care
hospital
5.8 10.3 28.2 <0.001
Anticoagulants – low molecular weight heparins/unfractionated heparin,
fondaparinux, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin
II receptor blockers, P2Y12-receptor inhibitors – ticlopidine/clopidogrel/ticagrelol,
CABG coronary artery bypass grafting, PCI percutaneous coronary intervention,
STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment
elevation myocardial infarction
Table 5 Medications prescribed for outpatient use in tertiary
and secondary care hospitals
Year 2001 Year 2007 Year 2011 P value
for trend% % %
Tertiary care hospitals n = 181 n = 290 n = 261
Aspirin 85.1 93.1 95.4 <0.001
P2Y12-receptor inhibitors 18.2 64.8 72.8 <0.001
Betablockers 71.3 80.0 85.4 <0.001
ACEi/ARB 66.3 77.2 84.7 <0.001
Statins 31.5 73.4 80.8 <0.001
Nitrates 61.9 22.1 15.8 <0.001
Secondary care hospitals n = 163 n = 224 n = 184
Aspirin 79.8 82.6 91.3 0.004
P2Y12-receptor inhibitors 0.6 10.7 32.8 <0.001
Betablockers 68.7 80.9 82.8 0.001
ACEi/ARB 37.4 68.9 68.3 <0.001
Statins 14.7 37.3 65.6 <0.001
Nitrates 85.3 58.2 41.4 <0.001
ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor
blockers, P2Y12-receptor inhibitors – ticlopidine/clopidogrel/ticagrelol
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academic hospitals, staffed less frequently with certified
cardiologists, is another plausible explanation [28, 29].
However, utilization rates of recommended drugs in the
tertiary care hospitals are similar with corresponding
rates from the UK, Sweden, and the US [30]. Also, pa-
tient compliance with suggested medications plays an
important role in determining the prognosis. Failure to
adhere to suggested therapies leads to more frequent hos-
pital readmissions and has a negative impact on mortality
[31, 32]. Similar problems related to the compliance with
suggested drugs after AMI have been previously described
in Estonia [33].
Another noteworthy finding from the study is the big
proportion of patients who present late after symptom
onset. Longer ischaemic times are associated with more
myocardial damage and have adverse impact on out-
come [34, 35]. Approximately 43 % of patients who
present later than 12 h after symptom onset explain why
reperfusion rates have remained low in the secondary
care hospitals. Unfortunately, presentation delays did
not show decrease over time.
Treatment of AMI patients improved mainly in the
tertiary care hospitals with the main changes occurring
during the first part of the study period. Inconsistency in
Table 6 Mortality of acute myocardial infarction patients primarily hospitalized into tertiary and secondary care hospitals
Mortality 2001 2007 2011 P value
for trend,
unadjusted











Tertiary care hospitals 17.6 13.1 13.2 0.181 0.97 (0.926–1.015) 0.061 0.96 (0.913–1.002)
Secondary care hospitals 20.2 22.5 12.4 0.022 0.96 (0.920–0.994) 0.003 0.94 (0.904–0.980)
1-year
Tertiary care hospitals 29.5 24.5 20.2 0.026 0.96 (0.928–0.995) 0.004 0.95 (0.917–0.984)
Secondary care hospitals 32.4 35.0 23.1 0.026 0.97 (0.938–0.996) 0.006 0.95 (0.918–0.977)
aadjusted for age, sex, AMI subtype (STEMI vs NSTEMI), previous myocardial infarction, previous heart failure, diabetes, hypertension
STEMI ST-segment elevation myocardial infarction, NSTEMI Non-ST-segment elevation myocardial infarction, HR hazard ratio, CI confidence interval
Fig. 2 Cumulative mortality hazards of patients hospitalized primarily into secondary and tertiary care hospitals. HR – hazard ratio, CI – confidence interval
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the speed of implementation of new treatment strategies
was reflected as a marked mortality gap in 2007 between
the secondary and the tertiary care hospitals. By the
2011, the differences in treatment persisted, but a signifi-
cant proportion of patients were transferred for further
management to the tertiary care hospitals. Consequently,
the noticeable mortality gap between the secondary and
the tertiary care hospitals was no longer present in 2011.
A similar initial large variation in treatments between
different hospitals and gradual lowering of short- and
long-term mortality are previously described in Sweden
for period 1996─2007 [36] and in the US between 1995
and 2006 [37].
The present study has several limitations. The first
limitation is that it cannot prove clear causality of ob-
served decrease in the mortality rates. Through adjusting
for baseline characteristics, we can reduce the possibility
that differences in the patient population accounted for
the change, but causality between practice patterns and
outcomes should not be inferred. Secondly, the present
study describes three random patient samples from
studied years, thus not describing the complete AMI
population for the period. Consequently, the treat-
ment regimens in the present study may not be
exactly as of the whole AMI population. Thirdly, we
did not collect information about contraindications to
certain treatments; therefore, we were not able to
evaluate how big proportion of eligible patients re-
ceived recommended treatment. Fourthly, we did not
collect data about drug compliance and utilization of
other secondary prevention methods including smok-
ing cessation etc. The importance of compliance with
recommended antiplatelet therapy after coronary stent
implementation is highlighted in recent study, which
describes almost 5-fold increase in cardiac mortality
rates for patients who discontinued clopidogrel within
3-months after the PCI procedure [38]. Thus, we
were unable to account for the effect of these or any
other unmeasured confounders, which might have in-
fluence to the long-term outcome.
Conclusions
In this country-wide analysis covering period 2001─2011,
we reported a decrease in 1-year mortality of AMI pa-
tients. During the study period, prevalence of most co-
morbidities remained unchanged while AMI management
improved significantly. Guideline-recommended acute
phase treatments were increasingly used in the tertiary
care setting. Secondary care hospitals are still lagging be-
hind, but substantial amount of patients are now referred
to a tertiary care centre for more advanced care. In con-
clusion, we were able to demonstrate improved prognosis
for Estonian AMI patients during the decade from 2001
to 2011. Furthermore, we determined that the prognosis
does not depend on the hospital type where patient is
hospitalized primarily – by the end of the study
period, Estonian hospitals were functioning as an efficient
network, delivering quite equal care to AMI patients as it
was aimed by the Estonian Society of Cardiology.
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